|
Daehan New Pharm's 'Lipi-C Injection' Enters the Chinese Market
2012.06.07
|
|---|
|
Lipi-C Injection Enters the Chinese Market
Despite challenges such as drug price reductions and FTA agreements, the pharmaceutical industry is seeking breakthroughs through overseas market expansion.
On May 21, Daehan New Pharm Co., Ltd., a KOSDAQ-listed company, signed a three-year supply agreement with a Chinese pharmaceutical company (Guangdong Longkang) for its liver disease injection Phosphatidylcholine (brand name: Lipi-C Injection). After approximately 18 months of clinical trials, the product is expected to be released to the Chinese market, with sales projected to begin in 2014. The estimated revenue over the contract period is around KRW 30 billion (based on current transaction prices).
Phosphatidylcholine, a liver disease treatment injection, is a unique product originally monopolized by Germany’s Lipoid GmbH, which supplies the raw material under an exclusive agreement with global pharmaceutical giant Sanofi Aventis, dominating the global market. In South Korea, only two companies, including Daehan New Pharm, hold approval for sales under the Ministry of Food and Drug Safety’s PMS (Post-Marketing Surveillance) program. Meanwhile, Sanofi Aventis maintains exclusive rights in China, generating approximately KRW 100 billion in annual sales for liver and fatty liver treatments.
Daehan New Pharm has built its operations around specialization, focus, and globalization as its core strategy, aiming to become a healthcare pioneer that creates a richer world and happier lives through specialized products and customized solution-based marketing. The company operates its own wellness programs centered on vitamin and obesity treatment products, has achieved visible business results through innovative and differentiated strategies, and has already registered over 200 products in 40 countries.
The recent contract for Chinese market entry is the outcome of this specialized portfolio, international business experience, strategic networking, and determination to overcome current challenges — a synergy expected to become a major growth engine for the company.
Using the Lipi-C Injection’s entry into China as a foothold, Daehan New Pharm plans to expand its exports further within China and into Southeast Asian markets. The company’s strategic decision is expected to serve as a successful model for overcoming market difficulties in the pharmaceutical industry. |


Home